Related Experiment Video
Updated: Aug 9, 2025
05:17
Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451
Published on: April 18, 2025
292
Detecting Early Cognitive Decline in Alzheimer's Disease with Brain Synaptic Structural and Functional Evaluation
1Faculty of Medicine, Institute of Pathophysiology, University of Ljubljana, Zaloška 4, SI-1000 Ljubljana, Slovenia.
Biomedicines
|February 25, 2023
Summary
Early Alzheimer's (AD) detection uses brain imaging to find synaptic changes linked to cognitive decline. These biomarkers offer a new diagnostic approach for mild cognitive impairment.
Area of Science:
- Neuroscience
- Biomarkers
- Neuroimaging
Background:
- Alzheimer's disease (AD) involves progressive synaptic dysfunction and hippocampal atrophy, impacting memory.
- Early cognitive decline in AD correlates with measurable brain structural and functional changes.
- Advances in neuroimaging enable biomarker-based diagnosis beyond clinical symptoms.
Purpose of the Study:
- To review current methods for detecting early cognitive decline in Alzheimer's disease.
- To discuss the role of brain synaptic structural and functional markers in diagnosis.
- To highlight the transition towards biomarker-based diagnosis in at-risk individuals.
Main Methods:
- Review of recent literature on Alzheimer's disease biomarkers.
- Analysis of brain imaging techniques (functional imaging, quantitative EEG).
- Examination of cerebrospinal fluid and blood biomarkers.
Main Results:
- Hippocampal synaptic density loss is linked to altered functional connectivity in key brain networks.
- Structural and functional brain changes are quantifiable markers of early AD.
- Biomarker-based diagnosis is shifting AD detection paradigms.
Conclusions:
- Brain synaptic structural and functional markers are crucial for early AD detection.
- Neuroimaging and other biomarkers facilitate diagnosis in patients with mild cognitive impairment.
- This approach supports earlier intervention for Alzheimer's disease.
Keywords:
ATN biomarkersAlzheimer’s diseasecognitive declinefunctional connectivityhippocampuslarge-scale networksmemorystructural connectivitysynaptic densitysynaptic functionMore Related Videos
Related Concept Videos
01:26Alzheimer's Disease: Overview
582
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
582
01:03Long-term Depression
2.6K
Long-term depression, or LTD, is one of the ways by which synaptic plasticity—changes in the strength of chemical synapses—can occur in the brain. LTD is the process of synaptic weakening that occurs over time between pre and postsynaptic neuronal connections. The synaptic weakening of LTD works in opposition to synaptic strengthening by long-term potentiation (LTP) and together are the main mechanisms that underlie learning and memory.
Calcium Ion Concentration Mechanism
If over...
Calcium Ion Concentration Mechanism
If over...
2.6K
01:22Alzheimer's Disease: Treatment
234
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
234